PACIFIC BIOSCIENCES OF CALIFORNIA, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 58/100
What the filing says
PacBio reported Q3 2026 revenue of $40.6M (up 5.6% YoY from $38.4M), with 15 Revio and 35 Vega system placements. CFO Jim Gibson stepped down; Mark Van Oene became interim CFO. Cash/investments declined sharply to $199.4M from $298.7M YoY (33% reduction), while stockholders' equity swung from +$5.3M to -$61.4M. Company raised 2026 guidance to $155–160M revenue. Gross margins compressed 600 bps (42% to 36% non-GAAP) due to memory costs and Vega transition. Net loss per share improved slightly: $0.12 GAAP vs. $0.13 YoY.
Why this rating
Revenue modest vs. $370M market cap; cash burn and equity flip material. Leadership change moderate concern. Margin compression and guidance raise offset by tech adoption progress.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.